Although insufficient RCTs reported acquired resistance rates stratified by specific factors influencing DoR (i.e., PD-L1, TMB) for such analyses to be included in this report, the increased acquired resistance risk observed with PCT-containing regimens highlights the potential value of tailoring first-line treatment strategies in NSCLC on the basis of individual risk of resistance to ICI. Here, CD274 is linked to non-small cell lung carcinoma.